Novo Nordisk to buy PhIII kidney disease drug from Singapore's KBP Biosciences
Novo Nordisk will pay up to $1.3 billion to buy a small molecule currently in Phase III for uncontrolled hypertension and advanced chronic kidney disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.